Skip to Content
Merck
All Photos(1)

Documents

Y0001388

Candesartan cilexetil

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C33H34N6O6
CAS Number:
145040-37-5
Molecular Weight:
610.66
MDL number:
MFCD00871371
UNSPSC Code:
41116107
PubChem Substance ID:
329831396
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

candesartan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

InChI key

GHOSNRCGJFBJIB-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Candesartan cilexetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001387

Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001389

Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard

1087803

Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard

1087814

Candesartan cilexetil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1087825

Candesartan cilexetil Related Compound B, United States Pharmacopeia (USP) Reference Standard

1087847

Candesartan cilexetil Related Compound D, United States Pharmacopeia (USP) Reference Standard

1087869

Candesartan cilexetil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1087870

Candesartan cilexetil Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR2035

Candesartan cilexetil impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2021

Candesartan Cilexetil Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2036

Candesartan Cilexetil Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2020

Candesartan Cilexetil Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2018

Candesartan Cilexetil Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2022

Candesartan Cilexetil Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2019

Candesartan Cilexetil Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2017

Candesartan Cilexetil Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1248

Candesartan cilexetil, British Pharmacopoeia (BP) Reference Standard

BP1249

Candesartan Cilexetil Impurity Standard, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Warning

Hazard Statements

H361 - H400

Precautionary Statements

P280

Hazard Classifications

Aquatic Acute 1 - Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
Gerd Bönner et al.
Current medical research and opinion, 21(6), 935-940 (2005-06-23)
Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for
Peter A Meredith
Current medical research and opinion, 23(7), 1693-1705 (2007-06-26)
Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an
Naoki Ichikawa et al.
Neurological research, 37(2), 147-152 (2014-08-05)
The purpose of this study was to examine whether oral administration of an angiotensin II type 1 receptor blocker (ARB) inhibited in-stent neointimal hyperplasia in carotid arteries of hypercholesterolemic rabbits. Eleven male New Zealand white rabbits were subjected to endothelial
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service